The optional vena cava filters of ALN (with and without hook) - permanent or temporary, position themselves as one of the solutions recognized for its efficiency and its reliability for a large number of public health establishments as well as private in France and in Europe, and all over the world. These medical devices are indicated for the prevention of a pulmonary embolism.
Discover
Recent ALN innovation, the optional vena cava filter, ALN OATF (with and without hook) is entering the market for the latest generation of medical devices for the prevention of pulmonary embolism.
Discover
ALN proposes 3 benchmarks for the removal and/or repositioning kits to adapt themselves to the different clinical contexts and needs. These are the functional variations that allow the removal or the repositioning of the ALN vena cava filters. An additional innovation of our company, for a better prevention of the pulmonary embolism.
Discover
Deux catégories spécifiques sont à distinguer dès lors qu’il est question d’évoquer la maladie thrombo-embolique. D’une part ce que l’on nomme les TVP (Thromboses Veineuses Profondes), d’autre part les embolies pulmonaires. Les dispositifs médicaux implantables ALN s’avèrent l’une des solutions reconnues de prévention actuelles sur le marché.
Les embolies pulmonaires peuvent provoquer des hypertensions pulmonaires thromboemboliques chroniques et sont souvent associées à une forte morbi-mortalité. En effet, c’est une pathologie très fréquente, s’imposant même comme la 3ème cause de mortalité par maladie cardio-vasculaire dans le monde. Plus spécifiquement l’embolie pulmonaire présente des hauts facteurs de risques vitaux, provoquant en moyenne 35 000 hospitalisations en France chaque année et représentant 5% de la mortalité hospitalière.
Two specific categories are to be distinguished when referring to thromboembolic disease. On the one hand what is called DVT (Deep Venous Thrombosis), on the other hand pulmonary embolisms. ALN implantable medical devices are one of the recognized preventative solutions on the market today.
Pulmonary embolism can cause chronic thromboembolic pulmonary hypertension and are often associated with high morbi-mortality. Indeed, it is a very common pathology, even claiming to be the third leading cause of death from cardiovascular disease in the world. More specifically, pulmonary embolism has high vital risk factors, causing an average of 35,000 hospitalizations in France each year and representing 5% of hospital mortality
